ArticleCartilage2025
A Comprehensive Review of Auto- and Allogeneic Chondrocyte Transplantation in Animals and Humans From 1965 to 2025.
Article in Cartilage, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Articular Cartilage Tissue Engineering: Cells, Bioinstructive Scaffolds, Immunological Microenvironment, and Emerging Technologies.Bioengineering (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo review the history of chondrocyte transplantation, new approaches to treatment of human chondral and osteochondral defects, animal experiments, the choice of chondrocytes for transplantation, immunological features of human and animal chondrocytes and factors which could influence results of chondrocyte transplantation.DesignAs the material for review served numerous papers collected during our many years' chondrocyte studies supplemented by PubMed search.ResultsAutologous chondrocytes, expanded in culture, were successfully used to repair damaged human articular cartilage. Numerous modifications of the original procedure benefited from a better understanding of factors influencing chondrocyte differentiation. Immunological studies suggested that survival of allogeneic transplants of bioengineered human neocartilage may depend on both passive and active mechanisms of immune evasion. Human chondrocytes with deleted expression of MHC class I molecules produced cartilage which, after transplantation into monkey articular cartilage was attacked by NK cells.ConclusionsImmune response against human chondrocytes requires further investigation. It is already established that allogeneic chondrocytes are safe for treating chondral defects but not for healing osteochondral defects. Full reconstruction of cartilage defects by restoring anatomically identical hyaline cartilage seems not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.